 |
|
|
|
 |
egories |
 |
 |
New Addition |
 |
|
|
 |
Details: |
 |
|
|
Provides some general information highlighting the possible role of a drug agent by the pharmaceutical firm Schering-Plough.
|
| URL: |
|
| Title: |
|
| Description: |
Health, Conditions and Diseases, Cancer, Melanoma - Interferon for Melanoma. Provides some general information highlighting the possible role of a drug agent by the pharmaceutical firm Schering-Plough. |
| Specialized in: |
|
|
 |
Popular Sites |
 |
 |
Related Press |
 |
Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol (Popularity: ): Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ...
Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017 (Popularity: ): Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches ...
Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development (Popularity: ): Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development. ...
Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis (Popularity: ): Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment has been completed in the REFLEX ...
FLAVORx Research Institute Celebrates 6 Month Anniversary: Services Attract Interest from Diverse Markets (Popularity: ): Since its inception in mid-December, the FLAVORx Research Institute (FRI) has recorded an tremendous level of interest from pharmaceutical companies ...
|
 |
Related Articles |
 |
|
|
 |
|
 |
| |
| | |
|
|
|
© 2003-2008, ABC-Directory.Com. All Rights Reserved
|
|
|
 |
|
 |
|